Log in

NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Forecast & News

$34.70
-0.78 (-2.20 %)
(As of 04/2/2020 03:02 AM ET)
Today's Range
$34.13
Now: $34.70
$36.32
50-Day Range
$31.52
MA: $43.38
$53.68
52-Week Range
$27.77
Now: $34.70
$68.85
Volume724,888 shs
Average Volume718,391 shs
Market Capitalization$2.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Read More
Agios Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.91 million
Book Value$10.88 per share

Profitability

Net Income$-411,470,000.00
Net Margins-348.96%

Miscellaneous

Employees482
Market Cap$2.38 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.


Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

How has Agios Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGIO stock has decreased by 15.1% and is now trading at $34.70. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Agios Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agios Pharmaceuticals.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Agios Pharmaceuticals.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) released its quarterly earnings data on Thursday, February, 13th. The biopharmaceutical company reported ($1.60) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.72) by $0.12. The biopharmaceutical company earned $35.44 million during the quarter, compared to the consensus estimate of $33.72 million. Agios Pharmaceuticals had a negative net margin of 348.96% and a negative return on equity of 73.42%. The firm's revenue for the quarter was up 18.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.58) earnings per share. View Agios Pharmaceuticals' earnings history.

What price target have analysts set for AGIO?

12 analysts have issued 12-month price targets for Agios Pharmaceuticals' stock. Their forecasts range from $49.00 to $79.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $63.10 in the next year. This suggests a possible upside of 81.8% from the stock's current price. View analysts' price targets for Agios Pharmaceuticals.

Has Agios Pharmaceuticals been receiving favorable news coverage?

Press coverage about AGIO stock has been trending very negative on Thursday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Agios Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAgios Pharmaceuticals.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), bluebird bio (BLUE), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), Micron Technology (MU) and AbbVie (ABBV).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Jacqualyn A. Fouse, Chief Executive Officer & Director
  • Andrew J. Hirsch, CFO & Head-Corporate Development
  • Scott Biller, Chief Scientific Officer
  • Chris Bowden, Chief Medical Officer
  • Clive Patience, Senior Vice President-Technical Operations

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $34.70.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $2.38 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe. View additional information about Agios Pharmaceuticals.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is http://www.agios.com/.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  434 (Vote Outperform)
Underperform Votes:  365 (Vote Underperform)
Total Votes:  799
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel